Aspen Pharmacare's fortunes may finally be turning around but the coronavirus could have an impact on its business as people delay elective surgeries for fear of contracting the virus in hospital.

CEO Stephen Saad told shareholders at Aspen's interim results presentation that though the company does not have manufacturing operations in China, the virus outbreak would have consequences for it.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now